相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC) : patient-reported quality-of-life outcomes of a randomised, controlled, 3 trial
Per Fransson et al.
LANCET ONCOLOGY (2021)
Patient reported toxicity and quality of life after hypofractionated high-dose intensity-modulated radiotherapy for intermediate- and high risk prostate cancer
Jeroen Houben et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2021)
A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer
Julia Murray et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Derivation of Dose/Volume Constraints for the Anorectum from Clinician- and Patient-Reported Outcomes in the CHHiP Trial of Radiation Therapy Fractionation
Anna Wilkins et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer
Karen E. Hoffman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial
Julia Murray et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2020)
Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy A Phase 3 Randomized Clinical Trial
Deborah W. Bruner et al.
JAMA ONCOLOGY (2019)
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
Anders Widmark et al.
LANCET (2019)
Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO Trial
Ruud C. Wortel et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer
Talha Shaikh et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial
Daniel A. Hamstra et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer
Charles N. Catton et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer
W. Robert Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David Dearnaley et al.
LANCET ONCOLOGY (2016)
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
J. L. Donovan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
F. C. Hamdy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
Anna Wilkins et al.
LANCET ONCOLOGY (2015)
Differing Perceptions of Quality of Life in Patients With Prostate Cancer and Their Doctors
Geoffrey A. Sonn et al.
JOURNAL OF UROLOGY (2013)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
David Dearnaley et al.
LANCET ONCOLOGY (2012)
Late gastrointestinal and urogenital side-effects after radiotherapy - Incidence and prevalence. Subgroup-analysis within the prospective Austrian-German phase II multicenter trial for localized prostate cancer
Maximilian P. Schmid et al.
RADIOTHERAPY AND ONCOLOGY (2012)
Development and Validation of an Abbreviated Version of the Expanded Prostate Cancer Index Composite Instrument for Measuring Health-related Quality of Life Among Prostate Cancer Survivors
Konrad M. Szymanski et al.
UROLOGY (2010)
Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy-Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer
David Cella et al.
VALUE IN HEALTH (2009)
The quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 47772397)
Richard J. Stephens et al.
BJU INTERNATIONAL (2007)
Generalized ordered logit/partial proportional odds models for ordinal dependent variables
Richard Williams
STATA JOURNAL (2006)
Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer
JT Wei et al.
UROLOGY (2000)
分享论文
